



Clinical trial results:

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

Summary

EudraCT number	2017-001055-30
Trial protocol	ES AT FR HU GB BE PL IT
Global end of trial date	05 April 2022

Results information

Result version number	v1 (current)
This version publication date	14 April 2023
First version publication date	14 April 2023

Trial information

Trial identification

Sponsor protocol code	8228-002
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03443869
WHO universal trial number (UTN)	-
Other trial identifiers	Merck: MK-8228-002

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 April 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 April 2022
Global end of trial reached?	Yes
Global end of trial date	05 April 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks post-transplant.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 24
Country: Number of subjects enrolled	Australia: 35
Country: Number of subjects enrolled	Austria: 15
Country: Number of subjects enrolled	Belgium: 28
Country: Number of subjects enrolled	Canada: 41
Country: Number of subjects enrolled	Colombia: 4
Country: Number of subjects enrolled	France: 40
Country: Number of subjects enrolled	Germany: 45
Country: Number of subjects enrolled	Hungary: 17
Country: Number of subjects enrolled	Italy: 20
Country: Number of subjects enrolled	Mexico: 32
Country: Number of subjects enrolled	New Zealand: 10
Country: Number of subjects enrolled	Poland: 5
Country: Number of subjects enrolled	Spain: 42
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	United States: 241
Worldwide total number of subjects	601
EEA total number of subjects	212

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	495
From 65 to 84 years	106
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Male/Female participants of at least 18 years of age with receipt of a kidney transplant were enrolled in this trial.

Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Letermovir

Arm description:

LET 480 mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400-mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks

Arm type	Experimental
Investigational medicinal product name	Letermovir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

480 mg (or 240 mg when co-administered with cyclosporin A) once daily for 28 weeks

Investigational medicinal product name	Placebo to VGCV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Once daily for 28 weeks

Investigational medicinal product name	Acyclovir (ACV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg every 12 hours for 28 weeks

Arm title	Valganciclovir
------------------	----------------

Arm description:

900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Valganciclovir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
900 mg once daily for 28 weeks	
Investigational medicinal product name	Placebo to LET
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Once daily for 28 weeks	
Investigational medicinal product name	Placebo to ACV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Every 12 hours for 28 weeks	

Number of subjects in period 1	Letermovir	Valganciclovir
Started	301	300
Treated	292	297
Completed	256	266
Not completed	45	34
Consent withdrawn by subject	34	22
Physician decision	3	3
Death	3	3
Unknown	4	4
Lost to follow-up	1	2

Baseline characteristics

Reporting groups

Reporting group title	Letermovir
Reporting group description:	
LET 480 mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400-mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks	

Reporting group title	Valganciclovir
Reporting group description:	
900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks	

Reporting group values	Letermovir	Valganciclovir	Total
Number of subjects	301	300	601
Age Categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age Continuous Units: years			
arithmetic mean	49.6	49.5	
standard deviation	± 14.8	± 15.1	-
Gender Categorical Units: Participants			
Female	84	90	174
Male	217	210	427
Race Units: Subjects			
American Indian or Alaska Native	3	4	7
Asian	5	10	15
Black or African American	22	33	55
Multiple	9	6	15
White	259	246	505
Missing	3	1	4
Ethnicity Units: Subjects			
Hispanic or Latino	56	45	101
Not Hispanic or Latino	230	240	470
Not Reported	6	9	15
Unknown	5	4	9

Missing	4	2	6
---------	---	---	---

End points

End points reporting groups

Reporting group title	Letermovir
Reporting group description: LET 480 mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400-mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks	
Reporting group title	Valganciclovir
Reporting group description: 900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks	

Primary: Percentage of Participants with Adjudicated CMV Disease Through 52 weeks Post-transplant

End point title	Percentage of Participants with Adjudicated CMV Disease Through 52 weeks Post-transplant
End point description: CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Analysis population consisted of all randomized participants who received at least one dose of study treatment, were CMV seropositive organ donor/CMV seronegative organ recipient (D+/R-), and had no detectable CMV viral DNA (measured by central laboratory) on Day 1.	
End point type	Primary
End point timeframe: Up to 52 weeks	

End point values	Letermovir	Valganciclovir		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289	297		
Units: Percentage of Participants				
number (not applicable)	10.4	11.8		

Statistical analyses

Statistical analysis title	LET vs VGCV
Statistical analysis description: The Observed failure (OF) approach was used to handle missing values, that is participants who had discontinued prematurely from the study for any reason were not considered failures	
Comparison groups	Valganciclovir v Letermovir

Number of subjects included in analysis	586
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Stratum-adjusted Treatment Difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	3.8

Notes:

[1] - LET was concluded non-inferior to VGCV if the upper bound of the two-sided 95% CI for difference in percentage of participants with adjudicated CMV disease (LET – VGCV) was no higher than 10%

Secondary: Percentage of Participants with Adjudicated CMV Disease Through 28 weeks Post-transplant

End point title	Percentage of Participants with Adjudicated CMV Disease Through 28 weeks Post-transplant
-----------------	--

End point description:

CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded CAC. Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Analysis population consisted of all randomized participants who received at least one dose of study treatment, were CMV D+/R-, and had no detectable CMV viral DNA (measured by central laboratory) on Day 1.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 28 weeks

End point values	Letermovir	Valganciclovir		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289	297		
Units: Percentage of Participants				
number (not applicable)	0.0	1.7		

Statistical analyses

Statistical analysis title	LET vs VGCV
----------------------------	-------------

Statistical analysis description:

The Observed failure (OF) approach was used to handle missing values, that is participants who had discontinued prematurely from the study for any reason were not considered failures

Comparison groups	Letermovir v Valganciclovir
Number of subjects included in analysis	586
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Stratum-adjusted Treatment Difference
Point estimate	-1.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	0.1

Secondary: Percentage of Participants with any AE

End point title	Percentage of Participants with any AE
End point description:	
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The percentage of participants who experienced 1 or more AEs was reported. Analysis performed for all randomized participants who received at least one dose of study treatment.	
End point type	Secondary
End point timeframe:	
Up to 52 weeks	

End point values	Letermovir	Valganciclovir		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	292	297		
Units: Percentage of Participants				
number (not applicable)	92.8	92.9		

Statistical analyses

Statistical analysis title	LET vs VLGV
Comparison groups	Letermovir v Valganciclovir
Number of subjects included in analysis	589
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	4.2

Secondary: Time to Onset of Adjudicated CMV Disease through 52 weeks Post-

transplant

End point title	Time to Onset of Adjudicated CMV Disease through 52 weeks Post-transplant
-----------------	---

End point description:

The time to onset of adjudicated CMV disease was calculated in days, from the day of randomization to the day of onset of CMV disease as determined by the CAC. Note: 9999 indicated that the median time to event was not reached as fewer than half the participants reached this endpoint. Analysis population consisted of all randomized participants who received at least one dose of study treatment, were CMV D+/R-, and had no detectable CMV viral DNA (measured by central laboratory) on Day 1.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Letermovir	Valganciclovir		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289	297		
Units: Days				
median (confidence interval 95%)	9999 (9999 to 9999)	9999 (9999 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with any Drug-related Serious Adverse Event (SAE)

End point title	Percentage of Participants with any Drug-related Serious Adverse Event (SAE)
-----------------	--

End point description:

An SAE was an AE that resulted in death, was life threatening, resulted in persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, was associated with an overdose, was another important medical event. SAEs that the investigator determined the relationship of the AE to the treatment as at least possibly related were reported. Analysis performed for all randomized participants who received at least one dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Letermovir	Valganciclovir		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	292	297		
Units: Percentage of Participants				
number (not applicable)	1.4	5.1		

Statistical analyses

Statistical analysis title	LET vs VLGV
Comparison groups	Letemovir v Valganciclovir
Number of subjects included in analysis	589
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	-0.9

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 52 weeks

Adverse event reporting additional description:

All-Cause Mortality included all randomized participants. Non-serious and SAEs were reported for all randomized participants who received at least one dose of study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

Reporting groups

Reporting group title	Letermovir
-----------------------	------------

Reporting group description:

LET 480 mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400-mg capsule of ACV orally every 12 hours for 28 weeks

Reporting group title	Valganciclovir
-----------------------	----------------

Reporting group description:

900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks

Serious adverse events	Letermovir	Valganciclovir	
Total subjects affected by serious adverse events			
subjects affected / exposed	118 / 292 (40.41%)	129 / 297 (43.43%)	
number of deaths (all causes)	5	3	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular lymphoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Post transplant lymphoproliferative disorder			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Extremity necrosis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	4 / 292 (1.37%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	0 / 292 (0.00%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Hypotension			
subjects affected / exposed	1 / 292 (0.34%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery stenosis			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocele			
subjects affected / exposed	8 / 292 (2.74%)	5 / 297 (1.68%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

General disorders and administration site conditions			
Puncture site pain			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malacoplakia			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site necrosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site extravasation			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Discomfort			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Dehiscence			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	9 / 292 (3.08%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 10	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Transplant rejection			
subjects affected / exposed	6 / 292 (2.05%)	9 / 297 (3.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney transplant rejection			
subjects affected / exposed	5 / 292 (1.71%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumomediastinum			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	3 / 292 (1.03%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary mass			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device dislocation			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	7 / 292 (2.40%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count decreased			
subjects affected / exposed	0 / 292 (0.00%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Complications of transplanted kidney			
subjects affected / exposed	3 / 292 (1.03%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delayed graft function			
subjects affected / exposed	2 / 292 (0.68%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Femur fracture			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft haemorrhage			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site discharge			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site erythema			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site pain			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural urine leak			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal lymphocele			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal transplant failure			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft complication			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			

subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant failure			
subjects affected / exposed	1 / 292 (0.34%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral injury			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			

subjects affected / exposed	0 / 292 (0.00%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt thrombosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	4 / 292 (1.37%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 292 (0.00%)	4 / 297 (1.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	1 / 292 (0.34%)	5 / 297 (1.68%)	
occurrences causally related to treatment / all	1 / 1	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	2 / 292 (0.68%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sickle cell anaemia with crisis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	4 / 292 (1.37%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	2 / 4	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoplastic anaemia			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	2 / 292 (0.68%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	2 / 292 (0.68%)	9 / 297 (3.03%)	
occurrences causally related to treatment / all	2 / 2	6 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Incarcerated inguinal hernia			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	2 / 292 (0.68%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingivitis ulcerative			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	2 / 292 (0.68%)	8 / 297 (2.69%)	
occurrences causally related to treatment / all	1 / 2	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	0 / 292 (0.00%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overflow diarrhoea			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	8 / 292 (2.74%)	9 / 297 (3.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcapsular renal haematoma			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			

subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Focal segmental glomerulosclerosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
IgA nephropathy			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelocaliectasis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst haemorrhage			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haematoma			
subjects affected / exposed	1 / 292 (0.34%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	1 / 292 (0.34%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder tamponade			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	0 / 292 (0.00%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	2 / 292 (0.68%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinoma			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular necrosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Musculoskeletal and connective tissue disorders			
Spinal pain			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			

subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial pyelonephritis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenovirus infection			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			

subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronavirus infection			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus colitis			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus gastritis			
subjects affected / exposed	2 / 292 (0.68%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus hepatitis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	7 / 292 (2.40%)	8 / 297 (2.69%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus syndrome			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus viraemia			

subjects affected / exposed	2 / 292 (0.68%)	4 / 297 (1.35%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr virus infection			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected urinoma			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymph node tuberculosis			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Norovirus infection			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parvovirus B19 infection			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parvovirus infection			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile gangrene			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 292 (0.34%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia parainfluenzae viral			

subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyomavirus-associated nephropathy			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	1 / 292 (0.34%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	4 / 292 (1.37%)	4 / 297 (1.35%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	4 / 292 (1.37%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			

subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal graft infection			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 292 (0.00%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Urinary tract infection			
subjects affected / exposed	8 / 292 (2.74%)	8 / 297 (2.69%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 292 (0.34%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus			

subjects affected / exposed	2 / 292 (0.68%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 292 (0.34%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	2 / 292 (0.68%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 292 (0.34%)	3 / 297 (1.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperlipidaemia			
subjects affected / exposed	1 / 292 (0.34%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypervolaemia			

subjects affected / exposed	2 / 292 (0.68%)	0 / 297 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	1 / 292 (0.34%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophosphataemia			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
New onset diabetes after transplantation			
subjects affected / exposed	3 / 292 (1.03%)	2 / 297 (0.67%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	0 / 292 (0.00%)	1 / 297 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Letermovir	Valganciclovir	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	239 / 292 (81.85%)	243 / 297 (81.82%)	
Investigations			
White blood cell count decreased			
subjects affected / exposed	3 / 292 (1.03%)	15 / 297 (5.05%)	
occurrences (all)	4	20	
Blood creatinine increased			
subjects affected / exposed	26 / 292 (8.90%)	39 / 297 (13.13%)	
occurrences (all)	29	46	
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	8 / 292 (2.74%)	19 / 297 (6.40%)	
occurrences (all)	9	22	
Vascular disorders			
Hypertension			
subjects affected / exposed	38 / 292 (13.01%)	43 / 297 (14.48%)	
occurrences (all)	43	46	
Hypotension			
subjects affected / exposed	20 / 292 (6.85%)	13 / 297 (4.38%)	
occurrences (all)	21	14	
Nervous system disorders			
Tremor			
subjects affected / exposed	53 / 292 (18.15%)	52 / 297 (17.51%)	
occurrences (all)	56	52	
Headache			
subjects affected / exposed	23 / 292 (7.88%)	21 / 297 (7.07%)	
occurrences (all)	27	27	
Dizziness			
subjects affected / exposed	15 / 292 (5.14%)	11 / 297 (3.70%)	
occurrences (all)	17	14	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	24 / 292 (8.22%)	34 / 297 (11.45%)	
occurrences (all)	25	36	
Leukopenia			

subjects affected / exposed	35 / 292 (11.99%)	105 / 297 (35.35%)	
occurrences (all)	46	125	
Neutropenia			
subjects affected / exposed	7 / 292 (2.40%)	50 / 297 (16.84%)	
occurrences (all)	9	60	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	22 / 292 (7.53%)	24 / 297 (8.08%)	
occurrences (all)	24	29	
Oedema peripheral			
subjects affected / exposed	44 / 292 (15.07%)	47 / 297 (15.82%)	
occurrences (all)	52	61	
Fatigue			
subjects affected / exposed	21 / 292 (7.19%)	34 / 297 (11.45%)	
occurrences (all)	21	38	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	23 / 292 (7.88%)	26 / 297 (8.75%)	
occurrences (all)	31	32	
Nausea			
subjects affected / exposed	35 / 292 (11.99%)	37 / 297 (12.46%)	
occurrences (all)	40	48	
Dyspepsia			
subjects affected / exposed	19 / 292 (6.51%)	15 / 297 (5.05%)	
occurrences (all)	20	17	
Diarrhoea			
subjects affected / exposed	99 / 292 (33.90%)	85 / 297 (28.62%)	
occurrences (all)	130	101	
Constipation			
subjects affected / exposed	27 / 292 (9.25%)	31 / 297 (10.44%)	
occurrences (all)	28	36	
Abdominal pain			
subjects affected / exposed	21 / 292 (7.19%)	17 / 297 (5.72%)	
occurrences (all)	22	17	
Respiratory, thoracic and mediastinal disorders			

Dyspnoea			
subjects affected / exposed	5 / 292 (1.71%)	22 / 297 (7.41%)	
occurrences (all)	5	23	
Cough			
subjects affected / exposed	15 / 292 (5.14%)	23 / 297 (7.74%)	
occurrences (all)	16	26	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	16 / 292 (5.48%)	14 / 297 (4.71%)	
occurrences (all)	17	14	
Acute kidney injury			
subjects affected / exposed	15 / 292 (5.14%)	9 / 297 (3.03%)	
occurrences (all)	16	10	
Musculoskeletal and connective tissue disorders			
Muscle spasms			
subjects affected / exposed	9 / 292 (3.08%)	17 / 297 (5.72%)	
occurrences (all)	9	19	
Back pain			
subjects affected / exposed	18 / 292 (6.16%)	17 / 297 (5.72%)	
occurrences (all)	19	18	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	41 / 292 (14.04%)	45 / 297 (15.15%)	
occurrences (all)	51	60	
Polyomavirus viraemia			
subjects affected / exposed	11 / 292 (3.77%)	16 / 297 (5.39%)	
occurrences (all)	11	18	
Cytomegalovirus infection			
subjects affected / exposed	8 / 292 (2.74%)	15 / 297 (5.05%)	
occurrences (all)	9	15	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	10 / 292 (3.42%)	21 / 297 (7.07%)	
occurrences (all)	12	22	
Metabolic acidosis			

subjects affected / exposed	16 / 292 (5.48%)	14 / 297 (4.71%)	
occurrences (all)	17	15	
Hypophosphataemia			
subjects affected / exposed	35 / 292 (11.99%)	36 / 297 (12.12%)	
occurrences (all)	38	41	
Hypomagnesaemia			
subjects affected / exposed	41 / 292 (14.04%)	40 / 297 (13.47%)	
occurrences (all)	44	47	
Hypokalaemia			
subjects affected / exposed	19 / 292 (6.51%)	10 / 297 (3.37%)	
occurrences (all)	22	10	
Hyperkalaemia			
subjects affected / exposed	32 / 292 (10.96%)	38 / 297 (12.79%)	
occurrences (all)	36	44	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2018	Added the LET 240 mg dose group when administered intravenously (IV) without cyclosporin A
20 March 2018	Added two laboratory exclusion criteria for consistency with the VGCV product circular information
10 July 2018	Permitted potential participants to be consented and screened up to 5 days (inclusive) after transplant surgery instead of requiring the completion of all screening procedures prior to transplant
13 March 2019	Added strong and moderate inducers of transporters and/or enzymes to the list of prohibited medications
23 October 2019	Added the specific requirements for the IV infusion of LET

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported